3HP-2827

DRUG2 trials

Sponsors

3H (Suzhou) Pharmaceuticals Co., Ltd.

Conditions

Solid Tumors With FGFR2 Alterations, Adult

Phase 1

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Not yet recruitingNCT06287918

3H (Suzhou) Pharmaceuticals Co., Ltd.Solid Tumors With FGFR2 Alterations, Adult

Start: 2026-06-01End: 2028-06-01Target: 130Updated: 2026-01-27

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

RecruitingNCT06378593

3H (Suzhou) Pharmaceuticals Co., Ltd.Solid Tumors With FGFR2 Alterations, Adult

Start: 2024-06-17End: 2028-06-16Target: 130Updated: 2026-01-27

Related Papers

First-in-human phase I/II study of a highly selective FGFR2 inhibitor 3HP-2827 in patients with advanced solid tumors harboring <i>FGFR2</i> alterations.

Journal of Clinical Oncology2026-05-27